Eli Lilly (NYSE: LLY) Clarified That the Retatrutide Regulatory Submission Timeline Was Pushed From End-2026 to Q1 2027 as the Company Continues Gathering Manufacturing and Quality Control Data Required for the FDA Biologics License Application; The TRIUMPH-1 Phase 3 Trial Readout Updated Documented 28.3% Mean Weight Loss at 80 Weeks on the 12 mg Weekly Injection Arm in 2,339 Participants With Obesity Without Type 2 Diabetes, the Largest Weight-Loss Figure Reported in Any Phase 3 Obesity Trial to Date; Combined With TRIUMPH-2 (Obesity Plus T2D at Up to 20.8% Weight Loss and 1.6 pp HbA1c Reduction in 1,152 Participants), TRIUMPH-3 (Additional Confirmatory Data), and TRIUMPH-4 (Obesity Plus Knee Osteoarthritis at 28.7% Weight Loss and 75.8% WOMAC Pain Reduction), the Retatrutide Package Now Anchors Four Major Indication Frames With Additional TRIUMPH Readouts (Obstructive Sleep Apnea, Chronic Lower Back Pain, Cardio-Renal-Metabolic Outcomes) Expected Across 2026
Eli Lilly (NYSE: LLY) clarified that the retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple agonist peptide) regulatory submission timeline was pushed from end-2026 to Q1 2027 as the company continues gathering manufacturing and quality control data required for the FDA Biologics License Application. TRIUMPH-1 (obesity without type 2 diabetes) Phase 3 readout updated documented 28.3% mean weight loss at 80 weeks on the 12 mg weekly injection arm in 2,339 participants, the largest weight-loss figure reported in any Phase 3 obesity trial to date. Combined with TRIUMPH-2 (obesity plus type 2 diabetes at up to 20.8% weight loss and 1.6 percentage point HbA1c reduction in 1,152 participants), TRIUMPH-3 (additional confirmatory data), and TRIUMPH-4 (obesity plus knee osteoarthritis at 28.7% weight loss and 75.8% WOMAC pain reduction), the retatrutide package now anchors four major indication frames. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. The Q1 2027 filing timeline shift is a modest delay from prior end-2026 signaling but reflects manufacturing-scale challenges typical of peptide APIs at the projected multi-billion-dollar commercial demand level (semaglutide and tirzepatide combined are already at roughly $80 billion annual revenue). Potential FDA approval expected in 2027 to 2028 following the standard 10-month review or 6-month priority review if a Priority Review Voucher (PRV) is deployed. Retatrutide will likely reshape the entire obesity drug class ceiling on the injectable side once approved.